Cargando…
Live Influenza Vaccine Provides Early Protection against Homologous and Heterologous Influenza and May Prevent Post-Influenza Pneumococcal Infections in Mice
Influenza and S. pneumoniae infections are a significant cause of morbidity and mortality worldwide. Intranasal live influenza vaccine (LAIV) may prevent influenza-related bacterial complications. The objectives of the study are to estimate resistance against early influenza infection and post-influ...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228789/ https://www.ncbi.nlm.nih.gov/pubmed/35744668 http://dx.doi.org/10.3390/microorganisms10061150 |
_version_ | 1784734567479902208 |
---|---|
author | Desheva, Yulia Leontieva, Galina Kramskaya, Tatiana Losev, Igor Rekstin, Andrey Petkova, Nadezhda Kudar, Polina Suvorov, Alexander |
author_facet | Desheva, Yulia Leontieva, Galina Kramskaya, Tatiana Losev, Igor Rekstin, Andrey Petkova, Nadezhda Kudar, Polina Suvorov, Alexander |
author_sort | Desheva, Yulia |
collection | PubMed |
description | Influenza and S. pneumoniae infections are a significant cause of morbidity and mortality worldwide. Intranasal live influenza vaccine (LAIV) may prevent influenza-related bacterial complications. The objectives of the study are to estimate resistance against early influenza infection and post-influenza pneumococcal pneumonia after LAIV in mice. Mice were administered intranasally the monovalent LAIV A/17/Mallard Netherlands/00/95(H7N3), A/17/South Africa/2013/01(H1N1)pdm09 or trivalent LAIV 2017–2018 years of formulation containing A/17/New York/15/5364(H1N1)pdm09 vaccine strain. LAIV demonstrated early protection against homologous and heterologous infections with A/South Africa/3626/2013 (H1N1) pdm09 influenza virus on day six, following immunization. Following boost immunization, trivalent LAIV demonstrated a pronounced protective effect both in terms of lethality and pneumococcal lung infection when S. pneumoniae infection was performed three days after the onset of influenza infection. Conclusion: LAIV provides early protection against homologous and heterologous viral infections and has a protective effect against post-influenza pneumococcal infection. These data suggest that the intranasal administration of LAIV may be useful during the cycle of circulation not only of influenza viruses, but also of other causative agents of acute respiratory infections. |
format | Online Article Text |
id | pubmed-9228789 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92287892022-06-25 Live Influenza Vaccine Provides Early Protection against Homologous and Heterologous Influenza and May Prevent Post-Influenza Pneumococcal Infections in Mice Desheva, Yulia Leontieva, Galina Kramskaya, Tatiana Losev, Igor Rekstin, Andrey Petkova, Nadezhda Kudar, Polina Suvorov, Alexander Microorganisms Article Influenza and S. pneumoniae infections are a significant cause of morbidity and mortality worldwide. Intranasal live influenza vaccine (LAIV) may prevent influenza-related bacterial complications. The objectives of the study are to estimate resistance against early influenza infection and post-influenza pneumococcal pneumonia after LAIV in mice. Mice were administered intranasally the monovalent LAIV A/17/Mallard Netherlands/00/95(H7N3), A/17/South Africa/2013/01(H1N1)pdm09 or trivalent LAIV 2017–2018 years of formulation containing A/17/New York/15/5364(H1N1)pdm09 vaccine strain. LAIV demonstrated early protection against homologous and heterologous infections with A/South Africa/3626/2013 (H1N1) pdm09 influenza virus on day six, following immunization. Following boost immunization, trivalent LAIV demonstrated a pronounced protective effect both in terms of lethality and pneumococcal lung infection when S. pneumoniae infection was performed three days after the onset of influenza infection. Conclusion: LAIV provides early protection against homologous and heterologous viral infections and has a protective effect against post-influenza pneumococcal infection. These data suggest that the intranasal administration of LAIV may be useful during the cycle of circulation not only of influenza viruses, but also of other causative agents of acute respiratory infections. MDPI 2022-06-02 /pmc/articles/PMC9228789/ /pubmed/35744668 http://dx.doi.org/10.3390/microorganisms10061150 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Desheva, Yulia Leontieva, Galina Kramskaya, Tatiana Losev, Igor Rekstin, Andrey Petkova, Nadezhda Kudar, Polina Suvorov, Alexander Live Influenza Vaccine Provides Early Protection against Homologous and Heterologous Influenza and May Prevent Post-Influenza Pneumococcal Infections in Mice |
title | Live Influenza Vaccine Provides Early Protection against Homologous and Heterologous Influenza and May Prevent Post-Influenza Pneumococcal Infections in Mice |
title_full | Live Influenza Vaccine Provides Early Protection against Homologous and Heterologous Influenza and May Prevent Post-Influenza Pneumococcal Infections in Mice |
title_fullStr | Live Influenza Vaccine Provides Early Protection against Homologous and Heterologous Influenza and May Prevent Post-Influenza Pneumococcal Infections in Mice |
title_full_unstemmed | Live Influenza Vaccine Provides Early Protection against Homologous and Heterologous Influenza and May Prevent Post-Influenza Pneumococcal Infections in Mice |
title_short | Live Influenza Vaccine Provides Early Protection against Homologous and Heterologous Influenza and May Prevent Post-Influenza Pneumococcal Infections in Mice |
title_sort | live influenza vaccine provides early protection against homologous and heterologous influenza and may prevent post-influenza pneumococcal infections in mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228789/ https://www.ncbi.nlm.nih.gov/pubmed/35744668 http://dx.doi.org/10.3390/microorganisms10061150 |
work_keys_str_mv | AT deshevayulia liveinfluenzavaccineprovidesearlyprotectionagainsthomologousandheterologousinfluenzaandmaypreventpostinfluenzapneumococcalinfectionsinmice AT leontievagalina liveinfluenzavaccineprovidesearlyprotectionagainsthomologousandheterologousinfluenzaandmaypreventpostinfluenzapneumococcalinfectionsinmice AT kramskayatatiana liveinfluenzavaccineprovidesearlyprotectionagainsthomologousandheterologousinfluenzaandmaypreventpostinfluenzapneumococcalinfectionsinmice AT losevigor liveinfluenzavaccineprovidesearlyprotectionagainsthomologousandheterologousinfluenzaandmaypreventpostinfluenzapneumococcalinfectionsinmice AT rekstinandrey liveinfluenzavaccineprovidesearlyprotectionagainsthomologousandheterologousinfluenzaandmaypreventpostinfluenzapneumococcalinfectionsinmice AT petkovanadezhda liveinfluenzavaccineprovidesearlyprotectionagainsthomologousandheterologousinfluenzaandmaypreventpostinfluenzapneumococcalinfectionsinmice AT kudarpolina liveinfluenzavaccineprovidesearlyprotectionagainsthomologousandheterologousinfluenzaandmaypreventpostinfluenzapneumococcalinfectionsinmice AT suvorovalexander liveinfluenzavaccineprovidesearlyprotectionagainsthomologousandheterologousinfluenzaandmaypreventpostinfluenzapneumococcalinfectionsinmice |